Kate Sasser
Overview
Explore the profile of Kate Sasser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura Y, Kaneva K, Lo C, Neems D, Freaney J, Boulos H, et al.
Clin Cancer Res
. 2024 Nov;
31(2):328-338.
PMID: 39513962
Purpose: Analysis of ctDNA may enable early identification of patients likely to relapse, presenting an opportunity for early interventions and improved outcomes. Tumor-naïve plasma-only approaches for minimal residual disease (MRD)...
2.
Owen D, Ben-Shachar R, Feliciano J, Gai L, Beauchamp K, Rivers Z, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2442970.
PMID: 39495511
Importance: The National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer suggest that RNA next-generation sequencing (NGS) may improve the detection of fusions and splicing variants compared with...
3.
Gentzler R, Guittar J, Mitra A, Iams W, Driessen T, Schwind R, et al.
Oncol Ther
. 2024 Jul;
12(3):509-524.
PMID: 39037536
Introduction: A dynamic molecular biomarker that can identify early efficacy of immune checkpoint inhibitor (ICI) therapy remains an unmet clinical need. Here we evaluate if a novel circulating tumor DNA...
4.
Li T, Hiemstra I, Chiu C, Oliveri R, Elliott B, DeMarco D, et al.
Clin Pharmacol Ther
. 2022 Aug;
112(5):1108-1119.
PMID: 35996883
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion...
5.
Muik A, Adams 3rd H, Gieseke F, Altintas I, Schoedel K, Blum J, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35688554
Background: Despite the preclinical promise of CD40 and 4-1BB as immuno-oncology targets, clinical efforts evaluating CD40 and 4-1BB agonists as monotherapy have found limited success. DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel...
6.
Muik A, Altintas I, Gieseke F, Schoedel K, Burm S, Toker A, et al.
Oncoimmunology
. 2022 Feb;
11(1):2030135.
PMID: 35186440
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with...
7.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, et al.
Cancer Discov
. 2022 Feb;
12(5):1248-1265.
PMID: 35176764
Significance: DuoBody-PD-L1×4-1BB (GEN1046) is a first-in-class bispecific immunotherapy with a manageable safety profile and encouraging preclinical and early clinical activity. With its ability to confer clinical benefit in tumors typically...
8.
Naicker S, Feerick C, Lynch K, Swan D, McEllistrim C, Henderson R, et al.
Oncoimmunology
. 2021 Feb;
10(1):1859263.
PMID: 33552684
Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone...
9.
Zhang Z, Yang Y, Zhou Y, Fang H, Yuan M, Sasser K, et al.
J Hum Genet
. 2020 Nov;
66(5):509-518.
PMID: 33177701
Mutual exclusivity analyses provide an effective tool to identify driver genes from passenger genes for cancer studies. Various algorithms have been developed for the detection of mutual exclusivity, but controlling...
10.
Yuan M, Zhu Z, Yang Y, Zhao M, Sasser K, Hamadeh H, et al.
Stat Methods Med Res
. 2020 Aug;
30(1):233-243.
PMID: 32838650
Nonlinear mixed-effects modeling is one of the most popular tools for analyzing repeated measurement data, particularly for applications in the biomedical fields. Multiple integration and nonlinear optimization are the two...